Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Zynerba Pharma CS (NQ: ZYNE ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Oct 10, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Zynerba Pharma CS < Previous 1 2 3 4 5 6 7 8 9 10 Next > Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference March 01, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Friday February 24, 2023 On Friday, 135 companies reached new 52-week lows. Via Benzinga ZYNE: Nano-Cap Company That Is Focused On Treatments For Neuropsychiatric Disorders February 20, 2023 Given the progress of its clinical trials, and its latest quarterly financials, Zynerba appears to be an excellent buy-and-hold investment consideration. Via Talk Markets 12 Health Care Stocks Moving In Friday's After-Market Session January 27, 2023 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session January 24, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session January 18, 2023 Via Benzinga What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper January 11, 2023 Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), announced the publication of a paper entitled, “Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol... Via Benzinga Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome January 11, 2023 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Wednesday December 28, 2022 On Wednesday, 258 companies hit new 52-week lows. Via Benzinga Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome December 21, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session December 20, 2022 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session December 06, 2022 Gainers Via Benzinga CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals December 05, 2022 Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. Via Benzinga Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology December 05, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology November 29, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders November 28, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session November 25, 2022 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session November 23, 2022 Via Benzinga Cannabis Legalization In Germany And Thailand, Gray Market In Brooklyn, Craft Weed Companies In Oregon November 18, 2022 German Opposition Official Against Recreational Marijuana Legalization Plan Via Benzinga Stocks That Hit 52-Week Lows On Wednesday November 16, 2022 On Wednesday, 70 companies set new 52-week lows. Via Benzinga Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome November 15, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details November 14, 2022 Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights Via Benzinga Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights November 14, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire A Comparison Of 5 Psychedelic ETFs And Indices November 11, 2022 A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector. Via Talk Markets The Psychedelic Drug Stocks Index Continued To Plummet Last Week November 07, 2022 In total, the Psychedelic Drug Stock Index went down 5.8% last week and is now down 64.9% YTD. Via Talk Markets Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome November 02, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire October Recap: Major Psychedelic Drug Stocks Declined 9.9% October 27, 2022 In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. Via Talk Markets Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week October 24, 2022 The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... Via Talk Markets Major Psychedelic Stock Downward Trend Continues October 24, 2022 The 8 constituents of our Psychedelic Drug Stocks Index continue to collectively show poor performance, down 4.6% more last week and now down 45.5% since the end of August. Via Talk Markets Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit October 17, 2022 From Zynerba Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
